Zacks: Analysts Anticipate Dynavax Technologies Co. (NASDAQ:DVAX) to Post -$0.34 EPS

Brokerages predict that Dynavax Technologies Co. (NASDAQ:DVAX) will post earnings per share (EPS) of ($0.34) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.33). Dynavax Technologies reported earnings per share of ($0.64) during the same quarter last year, which would suggest a positive year over year growth rate of 46.9%. The company is expected to report its next quarterly earnings report on Tuesday, February 25th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.04) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($2.00). For the next year, analysts anticipate that the firm will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.11) to ($0.90). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.10). The firm had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The business’s revenue was up 624.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) EPS.

A number of brokerages recently issued reports on DVAX. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright restated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. William Blair restated a “buy” rating on shares of Dynavax Technologies in a research note on Friday, August 16th. Finally, BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $12.63.

DVAX stock traded down $0.22 during midday trading on Monday, reaching $5.43. The stock had a trading volume of 1,504,786 shares, compared to its average volume of 1,309,014. The stock has a market cap of $479.68 million, a PE ratio of -2.13 and a beta of 0.56. The company has a debt-to-equity ratio of 5.48, a quick ratio of 4.09 and a current ratio of 4.94. The firm has a fifty day simple moving average of $5.20 and a two-hundred day simple moving average of $4.39. Dynavax Technologies has a 52-week low of $2.60 and a 52-week high of $12.42.

Institutional investors and hedge funds have recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. grew its position in Dynavax Technologies by 95.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,402 shares during the period. Bank of Montreal Can grew its position in Dynavax Technologies by 148.4% during the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 4,445 shares during the period. Wedbush Securities Inc. acquired a new stake in Dynavax Technologies during the 2nd quarter worth about $42,000. Ingalls & Snyder LLC acquired a new stake in Dynavax Technologies during the 3rd quarter worth about $52,000. Finally, M&T Bank Corp grew its position in Dynavax Technologies by 29.5% during the 2nd quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 3,116 shares during the period. 82.36% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.